Biogen’s tau-targeting drug candidate, diranucersen, showed a 26% slower rate of cognitive decline in a low-dose group during a Phase 2 trial, according to data presented at the Alzheimer’s Association International Conference (AAIC). While the drug significantly reduced tau protein levels by 50% to 65%, it failed to meet its primary endpoint of demonstrating a dose-response relationship.
Diranucersen Phase 2 Results and the Dose-Response Gap
Biogen revealed the results of the “CELIA” study, a global Phase 2 trial involving 416 patients with mild Alzheimer’s disease or mild cognitive impairment. The study aimed to prove that higher doses of diranucersen would lead to greater clinical benefits. However, the data contradicted this hypothesis.
According to Biogen, patients receiving the lowest dose (60mg every six months) experienced a 26% slower decline in cognitive and functional ability, measured by the Clinical Dementia Rating-Sum of Boxes (CDR-SB), compared to the placebo group. In contrast, the higher dose groups saw much smaller benefits: those receiving 115mg every six months showed a 14% slowdown, and those receiving 115mg every three months showed only a 9% slowdown.
Because the most significant benefit appeared at the lowest dose rather than the highest, the trial did not meet its primary endpoint. Despite this, the 60mg group showed consistent signals across secondary markers, including a 42% slowdown in cognitive decline on the ADAS-Cog13 scale and a 50% slowdown on the Mini-Mental State Examination (MMSE).
Targeting Tau Protein vs. Amyloid Beta
Most currently approved Alzheimer’s treatments, such as lecanemab and donanemab, focus on removing amyloid-beta plaques from the brain. Diranucersen takes a different approach by targeting the tau protein, which is closely linked to the actual death of neurons and the progression of dementia.
Developed by Ionis Pharmaceuticals and licensed to Biogen in 2019, diranucersen is an antisense oligonucleotide (ASO). It works by targeting the MAPT messenger RNA (mRNA) to stop the production of tau proteins before they can form the “tangles” that disrupt brain cell function. Biogen reported that diranucersen is the first tau-targeting therapy to show a reduction in both cerebrospinal fluid (CSF) tau levels and tau pathology as measured by PET imaging.
Safety Profile and Administration Challenges
The drug was generally well-tolerated, with most adverse events categorized as mild to moderate. Biogen noted that the drug did not cause Amyloid-Related Imaging Abnormalities (ARIA), such as brain swelling or microhemorrhages, which are common risks associated with amyloid-targeting antibodies.
However, the method of delivery remains a hurdle. Diranucersen is administered via intrathecal injection—meaning it’s injected into the spinal canal. Reported side effects included pain at the injection site, post-lumbar puncture syndrome, and temporary confusion that typically resolved within a week.
Comparison: Diranucersen vs. Amyloid Antibodies
| Feature | Amyloid Antibodies | Diranucersen (Tau ASO) |
|---|---|---|
| Target | Amyloid-beta plaques | Tau protein production |
| Delivery | Intravenous (IV) infusion | Intrathecal (Spinal) injection |
| Key Risk | ARIA (Brain swelling/bleeding) | Procedure-related pain/confusion |
Future Outlook and Phase 3 Planning
The U.S. Food and Drug Administration (FDA) granted diranucersen Fast Track designation in 2025 to accelerate its development. Biogen plans to move forward with a confirmatory Phase 3 trial based on the tau reduction and cognitive signals seen in the CELIA study.
The primary objective for the next phase will be to determine if the benefits seen in the 60mg dose group can be replicated in a larger patient population and to investigate why higher doses did not produce superior results. If successful, diranucersen could provide a critical new option for patients who do not respond to amyloid-based therapies.
Related reading